Update on AstraZeneca vaccine and vaccination programme

April 13th, 2021

All vaccination appointments on 13 April cancelled

As you may be aware, the HSE announced that all AstraZeneca COVID-19 vaccination appointments planned for today, Tuesday, 13 April have been cancelled. If you had an appointment to get the AstraZeneca COVID-19 vaccine today, you will be contacted to rearrange your appointment.

The HSE is now assessing the impact of a decision by the National Immunisation Advisory Committee (NIAC) recommending that the AstraZeneca vaccine be limited to people over 60 years of age.


AstraZeneca vaccine to be limited to people over 60 years

The committee has advised that the vaccine be limited to use in people over 60 years. The advice is based on an assessment of the risk of rare blood clotting side effects against the benefits of the vaccine, based on age.


Receiving your second dose of AstraZeneca vaccine

NIAC have said that the AstraZeneca vaccine remains a very effective vaccine. Most people under 60, who have already received their first dose of the AstraZeneca vaccine, will receive their second dose as planned.

  • NIAC advises, however, that a second dose should not be given to anyone who developed unusual blood clots with low platelets after the first dose.
  • Those aged 60 and older should receive their second dose 12 weeks after their first jab as scheduled.
  • People aged under 60 with a very high-risk or high-risk medical condition should also receive their second dose 12 weeks after their first jab as scheduled.
  • People under 60 without a very high-risk or high-risk condition will have the interval between their doses extended to 16 weeks to allow for further assessment of the benefits and risks of the vaccine, as more evidence becomes available.


Further roll-out of AstraZeneca vaccine for people aged 60-90 years

Most of the future AstraZeneca vaccines will be used just for people aged 60 to 90 years.


Full NIAC statement

You can read the statement from NIAC on the following link here.

MDI will continue to monitor official websites and keep you updated on any developments.

Share Now:

Categories: Covid-19News

1. Muscular Dystrophies

  • Becker muscular dystrophy
  • Duchenne muscular dystrophy
  • Manifesting carrier of Duchenne
  • Congenital muscular dystrophy
  •     •  General
  •     •  MDC1A (merosin-deficient congenital muscular dystrophy)
  •     •  Rigid spine syndrome (RSS)
  •     •  Ullrich congenital muscular dystrophies
  •     •  Bethlem myopathy
  • Emery-Dreifuss muscular dystrophy
  • Facioscapulohumeral muscular dystrophy
  • Limb-girdle types of muscular dystrophy (LGMD)
  •     •  General
  •     •  LGMD 1B (also known as Laminopathy)
  •     •  LGMD 1C (also known as Caveolinopathy)
  •     •  LGMD 2A (also known as Calpainopathy)
  •     •  LGMD 2B (also known as Dysferlinopathy)
  •     •  LGMD 2I
  • Ocular myopathies including ocularopharangeal muscular dystrophy

2. Myotonic Disorders

  • Congenital Myotonic Dystrophy
  • Myotonia
  • Myotonic Dystrophy

3. Congenital Myopathies

  • Central Core Myopathy
  • Congenital Fibre-type Disproportion Myopathy
  • Minicore (Multicore) myopathy
  • Myotubular or Centronuclear myopathy
  • Nemaline myopathy

4. Mitochondrial Myopathies

  • Mitochondrial Myopathies

5. Metabolic Disorders

  • Metabolic disorders (general)
  • McArdle’s Disease
  • Pompe’s Disease

6. Periodic Paralyses

  • Periodic Paralyses

7. Autoimmune Myositis

  • Polymyositis, Dermatomyositis and Sarcoid myopathy
  • Juvenile dermatomyositis
  • Inclusion body myositis

8. Spinal Muscular Atrophies

  • Severe (Type I)
  • Intermediate (Type II)
  • Mild (Type III)
  • Adult spinal muscular atrophy

9. Hereditary Motor and Sensory Neuropathies

  • (Also known as Charcot-Marie-Tooth or Peroneal muscular atrophy)

10. Disorders of the Neuromuscular Junction

  • Congenital myasthenic syndromes
  • Myasthenia Gravis

11. Friedreich’s Ataxia

  • Friedreich’s Ataxia

12. Other (Please Specify)

13. Unspecified